Co-infection of HBV and HCV among drug injected HIV (+) users

At Viet Duc Hospital from 1998 to 1999, 50 HIV(+) intravenous drug users, aged in average 26,4 were investigated. Anti HCV serum (+) in 62%, HCV Co-infected 30% and HBV 46%, co- infected with only HBV 16%, HIV, HBV, HCV 3 viruses co- infected 32%. The co- infected incidence was 50% in the year 1998 and 66% in 1999; 22% had not HBV and HCV co- infection. HBV and HCV co-infection characteristies: hiver cell degradation in 46,65% of HIV + HCV+ HBV co- infected; 68,75% in HIV+ HCV co- infection; 87,5% in HIV+ HBV co- infection. There were no much difference in term of the number of lymphocyte and monocyte between patients of 3 virus- infection, 2 virus infection and only HIV infection

The effectivement of antiretrovirus combining therapy for HIV positive patients in Hanoi

The study was conducted on 32 HIV positive patients (24 males and 8 females, over 15 years old, with CD4 T-cell counts <350 cell/mm3) who were treated with antiretrovirus therapy (Videx and Zerit) at Dong Da Hospital from Nov 2002 to Oct 2003. The results showed that ARV therapy is effective. The weight, Kanofsky scores, and T CD4 counts of patients were increased significantly after 6 months of treatment. Side effects included fatigue, headache, nausea, but only on first week. Enzyme amylase was increased slightly after 6 months of treatment